Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol
| Autor: | Karen W.L. Yee, Marc Poch Martell, Eshetu G. Atenafu, Aaron D. Schimmer, Vikas Gupta, Mark D. Minden, Joseph M. Brandwein, Andre C. Schuh |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Asparaginase medicine.medical_treatment Disease Disease-Free Survival chemistry.chemical_compound hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Retrospective Studies Chemotherapy business.industry Complete remission Age Factors Induction chemotherapy Imatinib Hematology Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma Surgery Survival Rate Regimen Treatment Outcome chemistry Lymphoblastic leukaemia Female business medicine.drug |
| Zdroj: | British journal of haematology. 163(4) |
| ISSN: | 1365-2141 |
| Popis: | All newly diagnosed patients aged 60-79 years with acute lymphoblastic leukaemia (ALL) receiving induction chemotherapy with a modified paediatric-based regimen over a 7-year period were retrospectively analysed (n = 51, median age 65 years). The treatment regimen consisted of induction, central nervous system prophylaxis, seven cycles of intensification and 24 cycles of maintenance. BCR-ABL1 negative patients received weekly asparaginase during intensification, while BCR-ABL1+ patients received daily imatinib. Post-remission therapy was given in an outpatient setting. The complete response rate was 75%, with an induction mortality of 20%; 6% of patients had resistant disease. 37% of patients who achieved a complete remission relapsed. The estimated 5-year overall survival was 40% for BCR-ABL1 negative and 47% for BCR-ABL1+ patients (P = not significant); the 5-year disease-free survival was 57% and 39%, respectively (P = NS). The post-induction phase was generally well tolerated, with 81% able to complete the intensification phase and proceed to maintenance. In conclusion, administration of this modified paediatric-based protocol is feasible and active for elderly patients with ALL. Survival is superior to most previously reported series in this age group, but remains worse compared to younger patients. Further improvement of the toxicity profile, particularly during induction, is required to improve outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text